Pegilodecakin.

It’s a long-acting IL-10 receptor agonist. By amplifying endogenous IL-10 levels, it results in expansion of tumor-specific T-cells and increased T-cell activity. The hope is, when combined with immunotherapy, it might further enhance treatment response. | Naing, Lancet Oncol 2019